paracetamol/caffeine galpharm 500 mg/65 mg tablett
galpharm healthcare limited - koffein; paracetamol - tablett - 500 mg/65 mg - paracetamol 500 mg aktiv substans; koffein 65 mg aktiv substans - kombinationer exkl. neuroleptika
zoonotic influenza vaccine seqirus
seqirus s.r.l. - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vacciner - active immunisation against h5 subtype of influenza a virus.
paracetamol/kodein actavis 1000 mg/60 mg filmdragerad tablett
actavis group ptc ehf. - kodeinfosfathemihydrat; paracetamol - filmdragerad tablett - 1000 mg/60 mg - kodeinfosfathemihydrat 60 mg aktiv substans; mannitol hjälpämne; sojalecitin hjälpämne; paracetamol 1000 mg aktiv substans - kombinationer exkl. neuroleptika
paracetamol/kodein evolan 500 mg/30 mg brustablett
evolan pharma ab - kodeinfosfathemihydrat; paracetamol - brustablett - 500 mg/30 mg - laktosmonohydrat hjälpämne; sorbitol hjälpämne; paracetamol 500 mg aktiv substans; kodeinfosfathemihydrat 30 mg aktiv substans - kombinationer exkl. neuroleptika
paracetamol/kodein actavis 500 mg/30 mg filmdragerad tablett
actavis group ptc ehf. - kodeinfosfathemihydrat; paracetamol - filmdragerad tablett - 500 mg/30 mg - kodeinfosfathemihydrat 30 mg aktiv substans; paracetamol 500 mg aktiv substans; sojalecitin hjälpämne; mannitol hjälpämne - kombinationer exkl. neuroleptika
paracetamol/codeine accord 500 mg/30 mg tablett
accord healthcare b.v. - kodeinfosfathemihydrat; paracetamol - tablett - 500 mg/30 mg - kodeinfosfathemihydrat 30 mg aktiv substans; paracetamol 500 mg aktiv substans
jcovden (previously covid-19 vaccine janssen)
janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacciner - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.
pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)
astrazeneca ab - reassortant influensavirus (levande dämpad) av följande stam: a / vietnam / 1203/2004 (h5n1) stam - influensa, människa - vacciner - profylax av influensa i en officiellt deklarerad pandemisk situation hos barn och ungdomar från 12 månader till yngre än 18 år. pandemic influenza vaccine h5n1 astrazeneca bör användas i enlighet med officiella riktlinjer.
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vacciner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.
spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.